Inotuzumab ozogamicin (solution)
Inotuzumab ozogamicin solution (CMC-544 solution) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin solution and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin solution has demonstrated efficacy against CD22+ B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin solution can be used in the research of acute lymphoblastic leukemia.
For research use only. We do not sell to patients.
- CAS No.: 635715-01-4
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Inotuzumab ozogamicin solution exerts highly potent cytotoxic activity against a vari-
ety of CD22-positive B-cell origin cancer cell lines[1].
Inotuzumab ozogamicin solution and G544
bind human CD22 with similar affinities (KD ≈ 150 pM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 635715-01-4
-
SMILES
[Inotuzumab ozogamicin (solution)]
-
Synonyms
CMC-544 (solution); PF-5208773 (solution); WAY-207294 (solution)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Shor B, et al. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67(2 Pt A):107-116. [Content Brief]
[2]. Kantarjian H, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403-411. [Content Brief]
[3]. Advani A, et al. Safety, pharmacokinetics, and preliminary clinical activity of Inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085-2093. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Inotuzumab ozogamicin (solution) Related Classifications
HY-P9959A Related Classifications
Powered by Bioz
- Inotuzumab ozogamicin (solution)
- 635715-01-4
- CMC-544 (solution)
- PF-5208773 (solution)
- WAY-207294 (solution)
- Antibody-Drug Conjugates (ADCs)
- CD22
- B-cell malignancy models
- diffuse large B-cell lymphoma
- non-Hodgkin’s lymphoma
- apoptosis
- calicheamicin
- DNA double-strand breaks
- B-cell
- follicular lymphoma
- acute lymphocytic leukemia
- Inhibitor
- inhibitor
- inhibit